Clinical-stage biopharmaceutical company developing integrin-based therapeutics for serious diseases, including oncology and other areas of unmet medical need
Clinical-stage biopharmaceutical company developing integrin-based therapeutics for serious diseases, including oncology and other areas of unmet medical need. Its lead candidate, PLN-101095, is an oral small-molecule dual inhibitor of αvβ8 and αvβ1 integrins being studied with pembrolizumab in advanced or metastatic solid tumors.